Grifols | GRFS - Ordinary Share Capital


Grifols reported EUR679.73M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.21M 2.2M Sep/2025
Arca Biopharma USD 37K 0 Mar/2025
aTyr Pharma USD 97.99M 97.9M Sep/2025
Bio Path USD 8K 2K Mar/2025
Brainstorm Cell Therapeutics USD 15K 1000 Mar/2025
Capricor Therapeutics USD 46K 0 Mar/2025
Cara Therapeutics USD 2K 3K Mar/2025
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Grifols EUR 679.73M 0 Sep/2025
Immunic USD 8K 4K Jun/2024
Infinity Pharmaceuticals USD 90K 1000 Jun/2023
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 19K 0 Sep/2024
TherapeuticsMD USD 11K 0 Sep/2023